ABSTRACT
Data on retrospective compensation claims for injuries caused by pharmaceutical drugs are prone to selection and reporting biases. Nevertheless, this case study of the antidiabetic drug benfluorex shows that such data can be used to estimate the cumulative incidence of drug-related injury, and to provide insights into its epidemiology. To this end, we develop a modelling framework for under-reporting of retrospective claims for compensation arising from drug damage. The model involves a longitudinal component related to attrition of cases over time, and a cross-sectional component related to incomplete reporting. We apply this model to cardiac valve surgery necessitated by exposure to benfluorex. Benfluorex was marketed in France between 1976 and 2009, when it was withdrawn because it caused valvular heart disease. A scandal erupted in 2010 over the scale of the damage caused by the drug. Since then, no further estimates of cumulative incidence have been published, though thousands of claims for compensation have been processed. The analysis combines compensation claims data and sociological survey data on benfluorex users, together with data on benfluorex sales and duration of treatment. We find a threshold of toxicity at about 6 months' exposure, and that at least 1690 individuals (95% CI 1290 to 2320) needed heart surgery to replace or repair valves damaged by exposure to benfluorex in France: a cumulative incidence of 3.68 per 10,000 (95% CI 2.68 to 5.34) benfluorex users or 3.22 per 10,000 (95% CI 2.48 to 4.39) person-years at risk above the exposure threshold. While these findings are tentative, they are consistent with those obtained previously using very different methods.
Subject(s)
Cardiac Surgical Procedures , Fenfluramine , Humans , Retrospective Studies , Fenfluramine/analogs & derivatives , Fenfluramine/adverse effects , France/epidemiology , Incidence , Female , Male , Cardiac Surgical Procedures/adverse effects , Middle Aged , Adult , Heart Valve Diseases/surgery , Heart Valve Diseases/chemically induced , Heart Valve Diseases/epidemiology , Compensation and Redress , Aged , Models, Statistical , Hypoglycemic Agents/adverse effects , Hypoglycemic Agents/therapeutic use , Insurance Claim ReviewABSTRACT
The hypolipidemic and hypoglycemic drug benfluorex was widely applied to treat type 2 diabetes mellitus and metabolic syndrome in overweight patients since 1976. However, benfluorex was connected to multiple cases of valvular heart disease and pulmonary arterial hypertension later on. Similar adverse drug reactions were previously found to be associated to the structurally related drug fenfluramine, which was attributed to the formation of its N-deethylated metabolite norfenfluramine. Even though norfenfluramine was known to be a common metabolite of fenfluramine and benfluorex, only fenfluramine was withdrawn from European and United States markets in 1997 while benfluorex remained available until 2009. In this work, the metabolism of benfluorex is simulated by an online hyphenation of electrochemistry and mass spectrometry and the observed transformation products are further characterized using liquid chromatography and high-resolution tandem mass spectrometry. Using this approach, norfenfluramine is found to be the main electrochemical transformation product of benfluorex. Considering the knowledge about norfenfluramine toxicity, rapid metabolite screening using electrochemistry hyphenated to mass spectrometry could have been used to predict the potential of benfluorex for adverse drug reactions early on, showcasing the value of electrochemical metabolism mimicry for rapid drug safety evaluation.
Subject(s)
Diabetes Mellitus, Type 2 , Norfenfluramine , Humans , Diabetes Mellitus, Type 2/drug therapy , Electrochemistry , Fenfluramine/adverse effects , Tandem Mass SpectrometryABSTRACT
Diabetes mellitus is a serious disease worldwide and causes other associated diseases. In this study, we observed the effect of streptozotocin (STZ)-induced diabetes and benfluorex treatment on muscular capillary ultrastructure. Adult male rats were used as the test subjects and each individual was intraperitoneally injected with one dose of STZ (45 mg/kg) to induce diabetes. Doses (50 mg/kg) of benfluorex were given to the subjects with tap water by intragastric gavage application once daily for 21 days. At the end of day 21, muscle tissues were obtained from animals and examined under transmission electron microscopy. From the data obtained with the electron microscope, it was observed that the control group had typical continuous capillary vascular structures in their muscles, while STZ caused disruptive disorder of the muscle cells in the capillary wall of the STZ-diabetic group. Additionally, the thickening of the basement membrane around endothelial cells, loss of mitochondrial crista in the muscle cells, enlarged endothelial cells, and narrowed vessel lumen were observed in the muscle tissue. The findings of our study revealed that STZ-induced diabetes disrupted the vascular structure, while benfluorex partially improved it.
ABSTRACT
Increasing evidence has revealed that the invasion and metastasis of HCC are intimately related to the low-glucose microenvironment, but the intrinsic regulatory mechanism remains unclear. It has been well documented that AMPK regulates the transcriptional expression of GLUT4 and its catalytic subunit AMPKα2 can negatively regulate the downstream target molecule HNF4A. Meanwhile, BORIS (Brother of the Regulator of Imprinted Sites) is able to modulate the Warburg effect by regulating the splicing of pyruvate kinase M2 (PKM2), a critical enzyme in glycolysis. Through bioinformatic analysis and a series of overexpression, knockdown, and complementation experiments, we demonstrated that HNF4A can directly act on BORIS and negatively regulate its expression, thereby inhibiting hepatoma cell motility and tumor metastasis, whereas BORIS can directly act on GLUT4 and positively regulate its expression to enhance hepatoma cell motility and tumor metastasis. We also found that HNF4A agonist (Benfluorex) and GLUT4 inhibitor (antiviral drug Ritonavir) can suppress HCC cell proliferation and glucose uptake. Taken together, these results all suggest that activation of the AMPKα2/HNF4A/BORIS/GLUT4 signaling pathway in a low-glucose microenvironment can significantly promote the invasion and metastasis of HCC cells, while HNF4A and GLUT4 may have important potential applications as prognostic or drug target molecules.
Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , AMP-Activated Protein Kinases/metabolism , Carcinoma, Hepatocellular/metabolism , Cell Line, Tumor , Cell Proliferation , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Neoplastic , Glucose/metabolism , Glucose Transporter Type 4 , Hepatocyte Nuclear Factor 4/genetics , Hepatocyte Nuclear Factor 4/metabolism , Humans , Liver Neoplasms/metabolism , Prognosis , Tumor MicroenvironmentABSTRACT
BACKGROUND: Anorectic drugs are overlooked as a cause of valvular heart disease (VHD). AIM: To describe the characteristics of a large population of patients with severe VHD who underwent cardiac surgery and had a history of benfluorex intake. METHODS: Retrospective observational and cross-sectional study of patients from a large French database (Office National d'Indemnisation des Accidents Médicaux). Clinical, echocardiographic, surgical and pathology findings were comprehensively collected from medical files. RESULTS: From a chart review of 9584 subjects, 1031 patients with VHD underwent cardiac surgery; 453 surgical patients were excluded because of VHD obviously unrelated to benfluorex exposure, six because of missing data and eight declined to participate. The final study population comprised 564 patients who had surgery between 1987 and 2019. Median age was 58 (interquartile range 50-65) years; 85% were female. Median duration of preoperative benfluorex exposure was 5.8 (3.3-10) years. Most patients had aortic and mitral valve disease. Pure or predominant aortic and/or mitral regurgitation were found in 84% of patients (n=471), and aortic or mitral stenosis (pure or combined with regurgitation) in 12% (n=67) and 15% (n=84), respectively. Overall, 403 aortic, 402 mitral and 64 tricuspid valve surgical procedures were collected. Aortic and mitral valves were found to be thickened, rigid and/or restrictive in most cases; restrictive tricuspid valve disease was seldom documented. Pathology was available in half of the population (276 patients); valvular fibrosis suggestive of drug-induced VHD was found in 222 patients, including 146 with expert examination. Mixed VHD aetiologies were discussed in 107 patients, including 54 with available pathology. CONCLUSIONS: Drug-induced VHD features are miscellaneous, including well-known restrictive valvular regurgitation, but also stenosis or combined regurgitation and stenosis. Besides a history of drug taking, thorough echocardiography and comprehensive surgical reports, pathology is key in the diagnostic procedure.
Subject(s)
Appetite Depressants , Heart Valve Diseases , Aged , Appetite Depressants/adverse effects , Constriction, Pathologic/chemically induced , Cross-Sectional Studies , Female , Fenfluramine/analogs & derivatives , Heart Valve Diseases/chemically induced , Heart Valve Diseases/diagnostic imaging , Heart Valve Diseases/epidemiology , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
BACKGROUND: Drug-induced valvular heart disease (DI-VHD) is a well-defined condition associated with specific pathology features. However, clinical presentations may broadly vary and thereby make DI-VHD diagnosis more challenging. CASE SUMMARY: We report two patients with a history of benfluorex administration, who developed extensive mitral calcific lesions which evolved towards caseous necrosis. DISCUSSION: Prospective follow-up over several years of these two patients who initially had typical DI-VHD findings provided monitoring evidence of extensive calcifications and subsequent caseous necrosis. These reports suggest a link between calcific heart injury and benfluorex exposure. The diagnosis of DI-VHD may be overlooked at this late stage.
ABSTRACT
Exposure to trichloroethylene (TCE) is linked to formation of congenital heart defects in humans and animals. Prior interactome analysis identified the transcription factor, Hepatocyte Nuclear Factor 4 alpha (HNF4a), as a potential target of TCE exposure. As a role for HNF4a is unknown in the heart, we examined developing avian hearts for HNF4a expression and for sensitivity to TCE and the HNF4a agonist, Benfluorex. In vitro analysis using a HNF4a reporter construct showed both TCE and HFN4a to be antagonists of HNF4a-mediated transcription at the concentrations tested. HNF4a mRNA is expressed transiently in the embryonic heart during valve formation and cardiac development. Embryos were examined for altered gene expression in the presence of TCE or Benfluorex. TCE altered expression of selected mRNAs including HNF4a, TRAF6 and CYP2C45. There was a transition between inhibition and induction of marker gene expression in embryos as TCE concentration increased. Benfluorex was largely inhibitory to selected markers. Echocardiography of exposed embryos showed reduced cardiac function with both TCE and Benfluorex. Cardiac contraction was reduced by 29% and 23%, respectively at 10 ppb. The effects of TCE and Benfluorex on autocrine regulation of HNF4a, selected markers and cardiac function argue for a functional interaction of TCE and HNF4a. Further, the dose-sensitive shift between inhibition and induction of marker expression may explain the nonmonotonic-like dose response observed with TCE exposure in the heart.
Subject(s)
Environmental Pollutants/toxicity , Heart/drug effects , Hepatocyte Nuclear Factor 4/genetics , Transcription, Genetic/drug effects , Trichloroethylene/toxicity , Animals , Chick Embryo , Dose-Response Relationship, Drug , Echocardiography , Fenfluramine/analogs & derivatives , Fenfluramine/pharmacology , Genes, Reporter , Heart/diagnostic imaging , Heart/embryology , Hep G2 Cells , Hepatocyte Nuclear Factor 4/agonists , Humans , Myocardium/metabolismABSTRACT
BACKGROUND: We have been intrigued by the observation that aortic stenosis (AS) may be associated with characteristic features of mitral drug-induced valvular heart disease (DI-VHD) in patients exposed to valvulopathic drugs, thus suggesting that beyond restrictive heart valve regurgitation, valvulopathic drugs may be involved in the pathogenesis of AS. METHODS: Herein are reported echocardiographic features, and pathological findings encountered in a series of patients suffering from both AS (mean gradient >15mmHg) and mitral DI-VHD after valvulopathic drugs exposure. History of rheumatic fever, chest radiation therapy, systemic disease or bicuspid aortic valve disease were exclusion criteria. RESULTS: Twenty-five (19 females, mean age 62years) patients having both AS and typical features of mitral DI-VHD were identified. Mean transaortic pressure gradient was 32+/-13mmHg. Aortic regurgitation was ≥ mild in 24 (96%) but trivial in one. Known history of aortic valve regurgitation following drug initiation prior the development of AS was previously diagnosed in 17 patients (68%). Six patients underwent aortic valve replacement and 3 both aortic and mitral valve replacement. In the 9 patients with pathology analysis, aortic valvular endocardium was markedly thickened by dense non-inflammatory fibrosis, a characteristic feature of DI-VHD. CONCLUSION: The association between AS and typical mitral DI-VHD after valvulopathic drug exposure may not be fortuitous. Aortic regurgitation was usually associated to AS and preceded AS in most cases but may be lacking. Pathology demonstrated the potential role of valvulopathic drugs in the development of AS.
Subject(s)
Aortic Valve Stenosis/chemically induced , Aortic Valve Stenosis/diagnostic imaging , Fenfluramine/adverse effects , Methysergide/adverse effects , Adult , Aged , Aged, 80 and over , Aortic Valve Stenosis/pathology , Female , Fenfluramine/analogs & derivatives , Humans , Male , Middle Aged , Retrospective StudiesABSTRACT
A simple LC/UV method for the simultaneous identification and quantification of Fluoxetine, Tiratricol, Benfluorex and Pseudoephedrine in slimming formulation is proposed. The method demonstrated effective in the analyses of herbal mixtures marketed in Italy as slimming capsules. Sixteen different herbal mixtures, selected among the most frequently compounded in Italian pharmacies, were tested as matrices. HPLC analyses were performed in a gradient mode on a C18 stationary phase The method was validated for accuracy, precision, linearity and selectivity. The limits of detection (LOD) were 3.4 µg/mL for Pseudoephedrine, 1.1 µg/mL for Triac, 0.9 µg/mL for Fluoxetine, and 0.8 µg/mL for Benfluorex. Repeatability and intermediate precision, expressed as percent of relative standard deviation, ranged from 3 to 7 and from 7 to 12, respectively. Given these limits, the developed method is proposed for the simple and cost effective screening of herbal products illegally adulterated with these four drugs known to enhance slimming effects.
Subject(s)
Appetite Depressants/analysis , Chemistry, Pharmaceutical/standards , Drug Contamination , Plant Preparations/analysis , Capsules , Chemistry, Pharmaceutical/methods , Chromatography, High Pressure Liquid/methods , Chromatography, High Pressure Liquid/standards , Chromatography, Liquid/methods , Chromatography, Liquid/standards , Drug Contamination/prevention & control , Reproducibility of Results , Spectrophotometry, Ultraviolet/methods , Spectrophotometry, Ultraviolet/standardsSubject(s)
Aortic Valve Insufficiency/chemically induced , Aortic Valve Insufficiency/surgery , Aortic Valve Prolapse/diagnosis , Aortic Valve/diagnostic imaging , Fenfluramine/analogs & derivatives , Heart Valve Prosthesis Implantation , Adult , Aged , Aortic Valve/pathology , Aortic Valve Insufficiency/diagnosis , Aortic Valve Prolapse/surgery , Appetite Depressants/adverse effects , Echocardiography , Female , Fenfluramine/adverse effects , Humans , Intraoperative Period , Male , Middle AgedABSTRACT
BACKGROUND: Fenfluramine and its derivatives have been associated with significant risk of developing valvular heart disease but its exact prevalence and severity are still debated. AIM: To evaluate the clinical and echocardiographic characteristics of patients hospitalized in a cardiology centre and who had past exposure to these drugs. METHODS: Between July 2011 and February 2012, patients admitted to the hospitalization and intensive care units at the University Centre of Montpellier, France were questioned about past exposure to fenfluramine or its derivatives. In patients who reported exposure, a questionnaire assessing prescribing patterns and medical history was proposed and echocardiography performed. All of the usual echocardiographic variables were analysed. We applied criteria from a French multicentre registry for diagnosis of drug-induced valvulopathy: leaflets and subvalvular apparatus thickening and retraction, leaflets loss of coaptation, no calcification, and no stenosis. RESULTS: Ninety-five patients exposed to these drugs were included. The majority were female (n=62, 65.3%), 53.2% (n=50) had diabetes and 90.5% (n=86) were exposed to benfluorex. Mean treatment duration was 52.3months (95% confidence interval [CI] 39.0-65.6). Valvular regurgitations were observed in 64.0% of patients (n=57) while 19.8% (n=17) had pulmonary hypertension. Highly probable fenfluramine-induced regurgitations were present in 18.6% (n=16) of patients, possibly fenfluramine-induced regurgitations in 38.2% (n=34) of patients, and unlikely fenfluramine-induced regurgitations in 25.8% (n=23) of patients. Highly probable fenfluramine-induced regurgitations were mild to moderate in severity in all except three patients. CONCLUSION: Considering the frequency of probable or possible fenfluramine-induced regurgitations and in the absence of definite knowledge about the evolution of drug-induced valvular disease, systematic questioning about fenfluramine use may be advisable in hospitalized cardiac patients.
Subject(s)
Appetite Depressants/adverse effects , Fenfluramine/analogs & derivatives , Fenfluramine/adverse effects , Heart Diseases/chemically induced , Heart Diseases/diagnosis , Aged , Dexfenfluramine/adverse effects , Female , Heart Diseases/diagnostic imaging , Humans , Male , Prospective Studies , UltrasonographySubject(s)
Fenfluramine/analogs & derivatives , Heart Valve Prosthesis Implantation , Mitral Valve Insufficiency , Mitral Valve , Ventricular Dysfunction, Left , Aged , Appetite Depressants/therapeutic use , Appetite Depressants/toxicity , Autopsy , Echocardiography/methods , Fatal Outcome , Fenfluramine/therapeutic use , Fenfluramine/toxicity , Heart Valve Prosthesis Implantation/adverse effects , Heart Valve Prosthesis Implantation/methods , Humans , Male , Mitral Valve/drug effects , Mitral Valve/pathology , Mitral Valve/surgery , Mitral Valve Insufficiency/chemically induced , Mitral Valve Insufficiency/diagnosis , Mitral Valve Insufficiency/physiopathology , Obesity/drug therapy , Stroke Volume , Ventricular Dysfunction, Left/diagnosis , Ventricular Dysfunction, Left/physiopathologySubject(s)
Fenfluramine/analogs & derivatives , Heart Valve Prosthesis Implantation , Mitral Valve Stenosis/chemically induced , Mitral Valve Stenosis/diagnostic imaging , Female , Fenfluramine/adverse effects , Humans , Hypolipidemic Agents/adverse effects , Middle Aged , Mitral Valve Stenosis/surgery , UltrasonographyABSTRACT
Benfluorex is responsible for the development of restrictive valvular regurgitation due to one of its metabolites, norfenfluramine. The 5-HT2B receptor, expressed on heart valves, acts as culprit receptor for drug-induced valvular heart disease (VHD). Stimulation of this receptor leads to the upregulation of target genes involved in the proliferation and stimulation of valvular interstitial cells through different intracellular pathways. Valve lesions essentially involve the mitral and/or aortic valves. The randomised prospective REGULATE trial shows a threefold increase in the incidence of valvular regurgitation in patients exposed to benfluorex. A cross-sectional trial shows that about 7% of patients without a history of VHD previously exposed to benfluorex present echocardiographic features of drug-induced VHD. The excess risks of hospitalisation for cardiac valvular insufficiency and of valvular replacement surgery were respectively estimated to 0.5 per 1000 and 0.2 per 1000 exposed patients per year. Recent data strongly suggest an aetiological link between benfluorex exposure and pulmonary arterial hypertension (PAH). The PAH development may be explained by serotonin, which creates a pulmonary vasoconstriction through potassium-channel blockade. Further studies should be conducted to determine the subsequent course of benfluorex-induced VHD and PAH, and to identify genetic, biological and clinical factors that determine individual susceptibility to developing such adverse effects.
Subject(s)
Fenfluramine/analogs & derivatives , Heart Valve Diseases/chemically induced , Hypertension, Pulmonary/chemically induced , Echocardiography , Fenfluramine/adverse effects , Fenfluramine/metabolism , Heart Valve Diseases/epidemiology , Heart Valve Diseases/physiopathology , Heart Valves/drug effects , Heart Valves/physiopathology , Humans , Hypertension, Pulmonary/epidemiology , Hypertension, Pulmonary/physiopathology , Hypolipidemic Agents/adverse effects , Norfenfluramine/adverse effects , Norfenfluramine/metabolism , Pulmonary Circulation/drug effects , Randomized Controlled Trials as Topic , Receptor, Serotonin, 5-HT2B/drug effects , Receptor, Serotonin, 5-HT2B/metabolismABSTRACT
AIMS: The epidemiologic link between benfluorex use and an increased global frequency of left heart valve regurgitation has been well documented. However, no data linking previous drug exposure to the frequency of diagnosis of drug-induced valvular heart disease (DI-VHD) are available. The present study was conducted to address this issue. METHODS AND RESULTS: This echocardiography reader-blinded, controlled study conducted in 10 centres between February 2010 and February 2012 prospectively included 835 subjects previously exposed to benfluorex referred by primary care physicians for echocardiography. Based on blinded off-line analysis, echocardiography findings were classified as: (i) DI-VHD⺠for patients with an echocardiographic diagnosis of DI-VHD, (ii) inconclusive, and (iii) DI-VHDâ» for patients without signs of DI-VHD. Fifty-seven (6.8%) patients exposed to benfluorex were classified as DI-VHDâº, 733 (87.8%) patients were classified as DI-VHDâ», and 45 (5.4%) were classified as inconclusive. Mitral and aortic DI-VHD were reported in 43 patients (5.1%) and 30 (3.6%) patients, respectively. Longer duration of exposure, female gender, smoking, and lower BMI were independently associated with a diagnosis of DI-VHD. Good inter-observer reproducibility was observed for the echocardiography classification (Kappa = 0.83, P < 0.00001). CONCLUSIONS: About 7% of patients without a history of heart valve disease previously exposed to benfluorex present echocardiography features of DI-VHD. Further studies are needed to study the natural history of DI-VHD and to identify risk factors for the development of drug-induced valve lesions.
Subject(s)
Aortic Valve Insufficiency/chemically induced , Appetite Depressants/adverse effects , Fenfluramine/analogs & derivatives , Hypolipidemic Agents/adverse effects , Mitral Valve Insufficiency/chemically induced , Analysis of Variance , Case-Control Studies , Diabetes Mellitus/drug therapy , Dyslipidemias/drug therapy , Echocardiography , Female , Fenfluramine/adverse effects , Humans , Male , Middle Aged , Obesity/drug therapy , Prospective Studies , Risk FactorsABSTRACT
BACKGROUND: Given the association between valvular heart disease and drugs that alter serotonin metabolism, concerns have been raised about the possibility of an association between selective serotonin reuptake inhibitor (SSRI) use and drug-induced valvular disease. In France, SSRI use has been suggested to be an important confounding factor in the development of heart valve lesions in patients exposed to benfluorex in the context of the 'Médiator scandal'. AIMS: To address the relationship between SSRI use and valve regurgitation and morphology in a large cohort of patients exposed to benfluorex. METHODS: Overall, 832 consecutive patients exposed to benfluorex prospectively referred to 10 centres underwent complete echocardiography examinations according to a standardized protocol. Echocardiograms were independently and blindly read off-line by two experts. RESULTS: Ninety patients had been exposed to SSRIs for 3 months or more. The proportions of patients with no or trivial, mild, moderate or severe mitral regurgitation (MR) or aortic regurgitation (AR) were not different between SSRI patients and non-SSRI patients (P=0.63 and 0.58, respectively). The frequencies of AR ≥ mild (20 [22.2%] vs 145 [19.5%]; P=0.55) and MR ≥ mild (14 [15.6%] vs 118 [15.9%]; P=0.93) were similar in SSRI patients and non-SSRI patients. The frequencies of aortic and mitral valve abnormalities suggestive of drug-induced toxicity were also similar in the two patient groups. Multivariable logistic regression analysis confirmed the absence of any identifiable relationship between AR or MR and morphological abnormalities and SSRI use in the present cohort. CONCLUSION: Exposure to SSRIs was not associated with an increased risk of heart valve regurgitation or morphological abnormalities suggestive of drug-induced toxicity in this large cohort of patients exposed to benfluorex.